Table 2 Variables within follow-up period and clinical outcomes

 Leukocyte count, 1000/μL

42.29 ± 10.76

39.49 ± 10.34

44.69 ± 10.67

 Hematopoietic progenitor cell, μL

49.78 ± 46.68

37.00 ± 29.01

59.56 ± 55.05

 Young cell, %

7.21 ± 5.06

7.10 ± 4.93

7.30 ± 5.23

 Segment, %

77.14 ± 7.86

76.86 ± 7.60

77.39 ± 8.18

 Neutrophil count, 1000/μL

32.76 ± 9.31

30.66 ± 9.44

34.56 ± 8.94

 Flow data: stem cell, %

0.35 ± 0.24

0.30 ± 0.18

0.40 ± 0.28

 Performance CV, %

4.68 ± 2.67

4.46 ± 2.71

4.87 ± 2.65

 CD34+ cell, 1000/μL

1.27 ± 0.90

0.87 ± 0.50

1.49 ± 1.00

 CD45+ cell, 1000/μL

343.05 ± 100.35

297.66 ± 103.38

366.74 ± 92.24

 Troponin-I after cell therapy

1.24 ± 3.30

1.02 ± 2.64

1.42 ± 3.78

 CCS angina score at baseline

2.55 ± 0.75

2.27 ± 0.64

2.80 ± 0.58

 CCS angina score ≥ 3, n (%)

36 (55.4%)

11 (36.7%)

25 (71.4%)

 CCS angina score at 3 months

0.57 ± 0.77

0.33 ± 0.55

0.77 ± 0.88

 CCS angina score at 6 months

0.50 ± 0.74

0.38 ± 0.62

0.60 ± 0.66

 CCS angina score at 12 months

0.33 ± 0.57

0.17 ± 0.47

0.47 ± 0.62

 NYHA Fc of dyspnea at baseline

1.71 ± 1.13

1.43 ± 1.17

1.94 ± 1.06

 NYHA Fc of dyspnea at 3 months

0.71 ± 0.88

0.37 ± 0.62

1.00 ± 0.97

 NYHA Fc of dyspnea at 6 months

0.53 ± 0.87

0.17 ± 0.47

0.83 ± 1.01

 NYHA Fc of dyspnea at 12 months

0.54 ± 0.90

0.21 ± 0.56

0.82 ± 1.03

 Endothelial dysfunction*, n (%)

38 (64.4%)

15 (57.7%)

23 (69.7%)

 CPET METs at baseline

5.08 ± 1.17

4.83 ± 1.19

5.24 ± 1.16

 CPET METs at 6 months

5.33 ± 1.44

5.22 ± 1.44

5.38 ± 1.46

 Difference of METs ^{6 months vs. baseline}

0.17 ± 1.20

0.47 ± 0.86

0.01 ± 1.33

 CMR LVEF at baseline, %

50.31 ± 14.52

52.69 ± 13.28

48.21 ± 15.42

 CMR LVEF at 6 months, %

52.93 ± 14.08

56.25 ± 12.33

50.03 ± 15.05

 Difference of LVEF^{6 months vs. baseline}

2.02 ± 4.96

2.71 ± 3.87

1.41 ± 5.74

 Angiogenesis score at baseline

1.57 ± 0.63

1.73 ± 0.57

1.43 ± 0.66

 Angiogenesis score ≥ 2, n (%)

36 (56.3%)

20 (66.7%)

16 (47.1%)

 Angiogenesis score at 9 months

2.60 ± 0.83

2.65 ± 0.70

2.56 ± 0.94

 3D echo LVEF at baseline, %

51.30 ± 10.62

49.41 ± 10.38

52.91 ± 10.71

 3D echo LVEF ≥ 50%, n (%)

40 (61.5%)

17 (56.7%)

23 (65.7%)

 3D echo LVEF ≤ 40%, n (%)

9 (13.8%)

6 (20.0%)

3 (8.6%)

 3D echo LVEF at 3 months, %

55.01 ± 11.46

56.18 ± 11.36

54.11 ± 11.63

 Difference of 3D LVEF^{3 months vs. baseline}

3.24 ± 5.91

5.71 ± 5.60

1.35 ± 5.49

 3D echo LVEF at 6 months, %

56.45 ± 12.56

57.40 ± 13.74

55.67 ± 11.64

 Difference of 3D LVEF^{6 months vs. baseline}

4.89 ± 7.94

7.47 ± 10.06

2.76 ± 4.80

 LA diameter, mm

42.17 ± 5.39

42.70 ± 4.94

41.71 ± 5.79

 LVEDD, mm

53.25 ± 8.42

53.22 ± 8.37

53.27 ± 8.59

 2D echo LVEF, %

54.32 ± 13.03

53.85 ± 13.82

54.72 ± 12.51

Grade 2 or 3 diast. dysfxn, n (%)

26 (40.6%)

7 (23.3%)

19 (55.9%)

 TVPG, mmHg

18.32 ± 11.66

19.52 ± 13.16

17.31 ± 10.33

 Moderate to severe MR, n (%)

9 (13.8%)

5 (16.7%)

4 (11.4%)

 3D echo LVEDV, mm³

87.11 ± 27.14

86.60 ± 26.43

87.51 ± 28.08

 Systolic dyssynchrony index, %

7.75 ± 7.25

8.48 ± 8.81

7.10 ± 5.54

 Composite endpoints^†, n (%)

31 (47.7%)

14 (46.7%)

17 (48.6%)

 All-cause mortality, n (%)

10 (15.4%)

4 (13.3%)

6 (17.1%)

 Cardiovascular death, n (%)

1 (1.5%)

1 (3.3%)

0 (0.0%)

 Acute myocardial infarction, n (%)

3 (4.6%)

1 (3.3%)

2 (5.7%)

 Hospitalization for HF, n (%)

13 (20.0%)

6 (20.0%)

7 (20.0%)

 Revascularization, n (%)

16 (24.6%)

9 (30.0%)

7 (20.0%)

 Sepsis, n (%)

6 (12.3%)

2 (6.7%)

6 (17.1%)